Document is current

Article History

Received: 25 November 2021

Accepted: 16 October 2022

First Online: 4 November 2022

Declarations

:

: This manuscript does not study human participants, human data or human tissues. The study is a financial analysis which does not specify human subject or research them.

: The study involves existing collection of data or records that contain only non-identifiable data about people.

: HKY, HGB, MJ, and JP are employed by and have a financial interest in Celltrion Healthcare, a company that may be affected by the research reported in the enclosed paper. FC has served as consultant to Mundipharma, AbbVie, MSD, Takeda, Janssen, Roche, and Celgene; received lecture fees from AbbVie, Ferring, Takeda, Allergy Therapeutics, and Janssen; and received unrestricted research grants from Giuliani, SOFAR, MS&D, Takeda, and AbbVie. MF has received consultant/lecture fees from AbbVie, Janssen, MSD, Celltrion, Pfizer, Tillotts, Ferring, Biogen, Boehringer, Gilead, Lilly, Gilead, Celgene, Fresenius, Takeda, and Amgen. LP-Breports personal fees from Galapagos, AbbVie, Janssen, Genentech, Ferring, Tillots, Pharmacosmos, Celltrion, Takeda, Boerhinger Ingelheim, Pfizer, Index Pharmaceuticals, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestle, Inotrem, Enterome, Allergan, MSD, Roche, Arena, Gilead, Hikma, Amgen, BMS, Vifor, Norgine; Mylan, Lilly, Fresenius Kabi, Oppilan Pharma, Sublimity Therapeutics, Applied Molecular Transport, OSE Immunotherapeutics, Enthera, Theravance; Pandion Therapeutics; grants from Abbvie, MSD, Takeda; stock options: CTMA. SS has received speaker fees from AbbVie, Dr Falk Pharmaceuticals, Shire, Celltrion, Takeda, and Janssen; educational grants from MSD, AbbVie, and Actavis; and is an advisory board member for AbbVie, Dr Falk Pharmaceuticals, Janssen, Takeda, Celltrion, and Vifor pharmaceuticals.